Plain-English translation of NCT06416410 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new two-drug combination called combined with works better than the current standard treatment (an immunotherapy drug plus chemotherapy) for advanced lung cancer patients who have a specific genetic change called KRAS p.G12C mutation. The trial will enroll about 392 people and compare how well the new treatment works and how patients tolerate it compared to the standard approach.
Currently, patients with this type of lung cancer are treated with immunotherapy combined with chemotherapy, but doctors hope this new treatment combination might be more effective or cause fewer side effects for people with this specific genetic mutation.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the new treatment group, you will take two oral medications (pills or capsules) on a 21-day cycle. If you are assigned to the standard treatment group, you will receive injections of three medications also on a 21-day cycle. You will have regular visits to your doctor for blood tests, imaging scans, and check-ins to monitor how the treatment is working and watch for side effects. The trial will continue until the cancer progresses or you cannot tolerate the treatment.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
China